The Hyderabad-based Suven Life Sciences Ltd received two product patents from Indian Patent Office for New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2027, the company stated in a release.

The products will be useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and  Schizophrenia.

"We are very pleased by the grant of these patents to Suven  for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally  and these patents are very important step in the execution of our strategy” says Venkat Jasti, CEO of Suven.

With these new patents, Suven has a total of eleven granted Indian patents on NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II, the company added.